arsenic has been researched along with carbostyril in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnett, AK; Hills, RK | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Deng, J; Li, Y; Luo, Q; Zhang, Z | 1 |
| Deng, JJ; Li, Y; Luo, QY; Zhang, ZZ | 1 |
| Lai, Y; Li, Y; Luo, Q; Zhang, Z | 1 |
5 other study(ies) available for arsenic and carbostyril
| Article | Year |
|---|---|
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Topics: 1-Naphthylamine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cyclin B1; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Naphthalimides; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolones; Up-Regulation | 2015 |
[4-amino-1,8-naphthalimide on the Sensitive effect of arsenic trioxide in hepatocellular carcinoma cells].
Topics: 1-Naphthylamine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Survival; DNA Damage; DNA Repair; Hep G2 Cells; Humans; Liver Neoplasms; Naphthalimides; Oxides; Quinolones | 2015 |
The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells.
Topics: 1-Naphthylamine; Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; DNA Damage; Hep G2 Cells; Humans; Inactivation, Metabolic; Liver Neoplasms; Naphthalimides; NF-kappa B; Oxidative Stress; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones; Reactive Oxygen Species | 2015 |